GlassScriptPhysician profile
Lucas Mcelwain
NPI 1952698433
$2,127.45
in general payments reported to CMS, 2019-2025
24 companies · $1,794 in 2025
The $1,794 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.87 · 2024: $317 · 2025: $1,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $249.23 | 2024-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $217.27 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $213.30 | 2022-2025 | Kisunla, Reyvow, Emgality |
| Alexion Pharmaceuticals, INC. | $196.96 | 2024-2025 | Ultomiris |
| Sk Life Science, INC. | $194.11 | 2025 | |
| Ucb, INC. | $190.48 | 2024-2025 | Rystiggo, Nayzilam, Briviact |
| Argenx US, INC. | $182.71 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $112.48 | 2024-2025 | |
| Lundbeck LLC | $97.66 | 2025 | Rexulti, Vyepti |
| Emd Serono, INC. | $66.42 | 2025 | |
| Eisai INC. | $60.93 | 2025 | |
| Tg Therapeutics, INC. | $54.14 | 2025 | |
| Tanabe Pharma America, INC. | $42.83 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $33.17 | 2025 | Austedo Xr |
| Merz Pharmaceuticals, LLC | $29.03 | 2024 | Xeomin, Inbrija |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $27.38 | 2024 | |
| Biogen, INC. | $27.01 | 2025 | Vumerity |
| Springworks Therapeutics, INC. | $24.50 | 2025 | Gomekli |
| Axsome Therapeutics, INC. | $21.73 | 2025 | Symbravo |
| Ani Pharmaceuticals, INC. | $21.15 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $18.47 | 2025 | Hyqvia |
| Novartis Pharmaceuticals Corporation | $16.37 | 2024 | |
| Resmed Corp | $15.46 | 2025 | |
| Neurelis, INC. | $14.66 | 2025 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucas Mcelwain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.